From Importer to Manufacturing Hub: How MENA Is Reshaping Pharmaceutical Production
September 2, 2026
MENA’s pharmaceutical industry is entering a new era. From Saudi Arabia’s manufacturing investments to the UAE’s growing role as a regional hub, the region is moving beyond pharmaceutical imports and building the infrastructure, capabilities and expertise needed to manufacture more complex medicines locally.
The pharmaceutical landscape across the Middle East and North Africa is entering a new phase. Governments and pharmaceutical companies are increasingly looking beyond traditional reliance on imported medicines, investing instead in local manufacturing, technology transfer and the development of more advanced biopharmaceutical capabilities.
Saudi Arabia is emerging as one of the strongest examples of this transformation. As part of its broader economic diversification strategy, the Kingdom is seeking to establish itself as a regional pharmaceutical and biotechnology hub, with investment increasingly moving from distribution and packaging toward full-scale manufacturing.
A major example came in February 2026, when German pharmaceutical company STADA announced an investment of more than €85 million to establish a new manufacturing facility in Saudi Arabia. Located in Sudair Industrial City, the 23,250-square-metre facility is expected to produce more than 300 million units annually and serve as a supply hub for Saudi Arabia and the wider MENA region.
The significance of investments like this extends beyond additional production capacity. Local manufacturing can help strengthen regional supply chains, improve medicine availability and reduce dependence on overseas production. It also creates opportunities for local expertise, technology transfer and the development of a more sophisticated pharmaceutical manufacturing ecosystem.
The shift is also reaching more complex products. In 2025, MS Pharma inaugurated a biologics manufacturing facility in Saudi Arabia, signalling the region's growing ambitions in biologics and biosimilars rather than focusing solely on conventional generics.
Saudi Arabia's state-backed Lifera is another important part of this strategy. Established by the Public Investment Fund, Lifera was created specifically to support the development of a leading pharmaceutical manufacturing platform in the Kingdom.
The UAE is pursuing a complementary strategy, combining pharmaceutical manufacturing with its established strengths in logistics, investment and international trade. In 2026, the Emirates Drug Establishment and Novo Nordisk agreed to cooperate on pharmaceutical manufacturing, advanced technologies, innovation and the development of local capabilities.
Meanwhile, Novo Nordisk announced plans for a regional distribution centre in the UAE that will serve markets across the Gulf, Africa and Central Asia, further strengthening the country's role in regional pharmaceutical supply chains.
Together, these developments point toward a broader transformation. MENA is no longer simply positioning itself as an important pharmaceutical market; it is increasingly positioning itself as a place where medicines are manufactured, technologies are transferred and new capabilities are developed.
The next challenge will be turning investment into sustainable manufacturing excellence. That means developing skilled workforces, strengthening regulatory capabilities, adopting advanced technologies and ensuring that new facilities can meet increasingly demanding global quality standards.
For pharmaceutical manufacturers, CDMOs and technology providers, this creates a significant opportunity. As MENA builds its next generation of production capacity, the region could become an increasingly important part of the global pharmaceutical manufacturing network.
Related
The Future of Sterile Fill-Finish: How Advanced Manufacturing Is Redefining Injectable Production
The future of sterile fill-finish is becoming faster, smarter and more automated. Jubilant Pharmova’s latest FDA-cleared isolator-based manufacturing line in Spokane highlights how advanced technology is helping the industry expand injectable production while strengthening sterility assurance, flexibility and quality.
Roche and Eli Lilly Advance Alzheimer’s Diagnosis With FDA-Cleared pTau217 Blood Test
A simple blood test could change how Alzheimer’s disease is detected and assessed. Roche and Eli Lilly’s newly FDA-cleared pTau217 test brings blood-based biomarker testing one step closer to routine clinical care, potentially making Alzheimer’s assessment more accessible, scalable and less invasive.
